COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

1 . A compound of Formula I:

or a pharmaceutically acceptable salt thereof or a tautomer thereof,

wherein:

Z is selected from the group consisting of a bond, CR 1 , C(R 3 ) 2 , N, and NR 2 ;

each of Y 1 , Y 2 , and Y 3 is independently selected from the group consisting of O, S, CR 1 , C(R 3 ) 2 , N, and NR 2 ;

Y 4 is C or N;

X 1 is selected from the group consisting of O, S, N, NR 2 , and CR 1 ;

X 2 is selected from the group consisting of O, S, N, NR 4 , and CR 5 ;

each is independently a single bond or a double bond, provided that the five-membered ring comprising Y 4 , X 1 , and X 2 is heteroaryl;

Q-A is defined according to (A) or (B) below:

(A)

Q is selected from the group consisting of: NH and N(C 1-6 alkyl) wherein the C 1-6 alkyl is optionally substituted with 1-2 independently selected R a ; and

A is:

(i) —(Y A1 ) n —Y A2 , wherein:

n is 0 or 1;

Y A1 is C 1-6 alkylene, which is optionally substituted with 1-6 substituents each independently selected from the group consisting of:

R a ;

C 6-10 aryl optionally substituted with 1-4 independently selected C 1-4 alkyl; and

heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heteroaryl ring is optionally substituted with 1-4 independently selected C 1-4 alkyl;

or

Y A1 is —Y A3 —Y A4 —Y A5 which is connected to Q via Y A3 wherein:

Y A3 is a C 1-3 alkylene optionally substituted with 1-2 independently selected R a ;

Y A4 is —O—, —NH—, or —S—; and

Y A5 is a bond or C 1-3 alkylene which is optionally substituted with 1-2 independently selected R a ; and

Y A2 is

(a) C 3-20 cycloalkyl or C 3-20 cycloalkenyl, each of which is optionally substituted with 1-4 R b ,

(b) C 6-20 aryl, which is optionally substituted with 1-4 R c ;

(c) heteroaryl of 5-20 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heteroaryl ring is optionally substituted with 1-4 independently selected R c ; or

(d) heterocyclyl or heterocycloalkenyl of 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heterocyclyl or heterocycloalkenyl ring is optionally substituted with 1-4 independently selected R b ,

or

(ii) —Z 1 —Z 2 —Z 3 , wherein:

Z 1 is C 1-3 alkylene, which is optionally substituted with 1-4 R a ;

Z 2 is —N(H)—, —N(R d )—, —O—, or —S—; and

Z 3 is C 2-7 alkyl, which is optionally substituted with 1-4 R a ;

or

(iii) C 1-20 alkyl, which is optionally substituted with 1-6 independently selected R a ,

or

Q and A, taken together, form:

 and

E is a ring of 3-16 ring atoms, wherein, 0-3 ring atoms are heteroatoms (in addition to the nitrogen atom that is present), each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the ring is optionally substituted with 1-4 independently selected R b ,

each occurrence of R 1 is independently selected from the group consisting of

H; halo; cyano; C 1-6 alkyl optionally substituted with 1-2 R a ; C 2-6 alkenyl; C 2-6 alkynyl; C 1-4 haloalkyl; C 1-4 alkoxy; C 1-4 haloalkoxy; -L 3 -L 4 -R i ; —S(O) 1-2 (C 1-4 alkyl); —S(O)(═NH)(C 1-4 alkyl); SF 5 ; —NR e R f ; —OH; oxo; —S(O) 1-2 (NR′R″); —C 1-4 thioalkoxy; —NO 2 ; —C(═O)(C 1-4 alkyl); —C(═O)O(C 1-4 alkyl); —C(═O)OH; and —C(═O)N(R′)(R″);

or a pair of R 1 on adjacent atoms, taken together with the atoms connecting them, form a ring of 3-10 ring atoms, wherein 0-2 ring atoms are heteroatoms each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 ; and wherein the ring is optionally substituted with 1-4 substituents each independently selected from the group consisting of C 1-6 alkyl, halo, C 1-6 haloalkyl, —OH, NR e R f , C 1-6 alkoxy, and C 1-6 haloalkoxy,

each occurrence of R 2 is independently selected from the group consisting of:

(i) C 1-6 alkyl, which is optionally substituted with 1-2 independently selected R a ;

(ii) C 3-6 cycloalkyl or C 3-6 cycloalkenyl;

(iii) heterocyclyl or heterocycloalkenyl of 3-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 ;

(iv) C 6-10 aryl;

(v) heteroaryl of 5-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 ;

(vi) —C(O)(C 1-4 alkyl);

(vii) —C(O)O(C 1-4 alkyl);

(viii) —CON(R′)(R″);

(ix) —S(O) 1-2 (NR′R″);

(x) —S(O) 1-2 (C 1-4 alkyl);

(xi) —OH;

(xii) C 1-4 alkoxy; and

(xiii) H;

or a pair of R 1 and R 2 on adjacent atoms, taken together with the atoms connecting them, form a ring of 3-10 ring atoms, wherein 0-2 ring atoms (in addition to the nitrogen atom to which the R 2 is attached) are heteroatoms each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 ; and wherein the ring is optionally substituted with 1-4 substituents each independently selected from the group consisting of C 1-6 alkyl, halo, C 1-6 haloalkyl, —OH, NR e R f , C 1-6 alkoxy, and C 1-6 haloalkoxy,

each occurrence of R 3 is independently selected from the group consisting of H; C 1-6 alkyl optionally substituted with 1-6 independently selected R a ; C 1-4 haloalkyl; —OH; —F; —Cl; —Br; —NR e R f ; C 1-4 alkoxy; C 1-4 haloalkoxy; —C(═O)(C 1-4 alkyl); —C(═O)O(C 1-4 alkyl); —C(═O)OH; —C(═O)N(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); cyano; and C 3-6 cycloalkyl or C 3-6 cycloalkenyl, each optionally substituted with 1-4 independently selected C 1-4 alkyl; or

two R 3 on the same carbon combine to form an oxo; or

a pair of R 3 on the same or on adjacent atoms, taken together with the atom(s) connecting them, form a ring of 3-10 ring atoms, wherein 0-2 ring atoms are heteroatoms each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 ; and wherein the ring is optionally substituted with 1-4 substituents each independently selected from the group consisting of C 1-6 alkyl, halo, C 1-6 haloalkyl, —OH, NR e R f , C 1-6 alkoxy, and C 1-6 haloalkoxy; or

a pair of R 1 and R 3 on adjacent atoms, taken together with the atoms connecting them, form a ring of 3-10 ring atoms, wherein 0-2 ring atoms are heteroatoms each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 ; and wherein the ring is optionally substituted with 1-4 substituents each independently selected from the group consisting of C 1-6 alkyl, halo, C 1-6 haloalkyl, —OH, NR e R f , C 1-6 alkoxy, and C 1-6 haloalkoxy; or

a pair of R 2 and R 3 on adjacent atoms, taken together with the atoms connecting them, form a ring of 3-10 ring atoms, wherein 0-2 ring atoms (in addition to the nitrogen atom to which the R 2 is attached) are heteroatoms each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 ; and wherein the ring is optionally substituted with 1-4 substituents each independently selected from the group consisting of C 1-6 alkyl, halo, C 1-6 haloalkyl, —OH, NR e R f , C 1-6 alkoxy, and C 1-6 haloalkoxy;

R 4 is selected from the group consisting of H and C 1-6 alkyl optionally substituted with 1-3 independently selected R a ;

R 5 is selected from the group consisting of H; halo; —OH; —C 1-4 alkyl; —C 1-4 haloalkyl; C 1-4 alkoxy; C 1-4 haloalkoxy; —C(═O)O(C 1-4 alkyl); —C(═O)(C 1-4 alkyl); —C(═O)OH; —CON(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); cyano, and C 3-6 cycloalkyl or C 3-6 cycloalkenyl, each optionally substituted with 1-4 independently selected C 1-4 alkyl;

R 6 is selected from the group consisting of H; C 1-6 alkyl optionally substituted with 1-3 independently selected R a ; —OH; C 1-4 alkoxy; C(═O)H; C(═O)(C 1-4 alkyl); C 6-10 aryl optionally substituted with 1-4 independently selected C 1-4 alkyl; and heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 and wherein the heteroaryl ring is optionally substituted with 1-4 independently selected C 1-4 alkyl;

each occurrence of R a is independently selected from the group consisting of: —OH; —F; —Cl; —Br; —NR e R f ; C 1-4 alkoxy; C 1-4 haloalkoxy; —C(═O)O(C 1-4 alkyl); —C(═O)(C 1-4 alkyl); —C(═O)OH; —CON(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); cyano, and C 3-6 cycloalkyl or C 3-6 cycloalkenyl, each optionally substituted with 1-4 independently selected C 1-4 alkyl;

each occurrence of R b is independently selected from the group consisting of: C 1-10 alkyl optionally substituted with 1-6 independently selected R a ; C 1-4 haloalkyl; —OH; oxo; —F; —Cl; —Br; —NR e R f ; C 1-4 alkoxy; C 1-4 haloalkoxy; —C(═O)(C 1-10 alkyl); —C(═O)O(C 1-4 alkyl); —C(═O)OH; —C(═O)N(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); cyano; and -L 1 -L 2 -R h ;

each occurrence of R c is independently selected from the group consisting of: halo; cyano; C 1-10 alkyl which is optionally substituted with 1-6 independently selected R a ; C 2-6 alkenyl; C 2-6 alkynyl; C 1-4 alkoxy optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkoxy; —S(O) 1-2 (C 1-4 alkyl) or —S(O) 1-2 (C 1-4 haloalkyl); —NR e R f ; —OH; —S(O) 1-2 (NR′R″); —C 1-4 thioalkoxy or —C 1-4 thiohaloalkoxy; —NO 2 ; —SF 5 ; —C(═O)(C 1-10 alkyl); —C(═O)O(C 1-4 alkyl); —C(═O)OH; —C(═O)N(R′)(R″); and -L 1 -L 2 -R h ;

R d is selected from the group consisting of: C 1-6 alkyl optionally substituted with 1-3 substituents each independently selected from the group consisting of halo and OH; C 3-6 cycloalkyl or C 3-6 cycloalkenyl, each optionally substituted with 1-3 substituents each independently selected from the group consisting of halo and OH; —C(O)(C 1-4 alkyl); —C(O)O(C 1-4 alkyl); —CON(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); —OH; and C 1-4 alkoxy;

each occurrence of R e and R f is independently selected from the group consisting of: H; C 1-6 alkyl; C 1-6 haloalkyl; C 3-6 cycloalkyl or C 3-6 cycloalkenyl; —C(O)(C 1-4 alkyl); —C(O)O(C 1-4 alkyl); —CON(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); —OH; and C 1-4 alkoxy; or R e and R f together with the nitrogen atom to which each is attached forms a ring of 3-8 ring atoms, wherein the ring has: (a) 1-7 ring carbon atoms, each of which is substituted with 1-2 substituents independently selected from the group consisting of H and C 1-3 alkyl; and (b) 0-3 ring heteroatoms (in addition to the nitrogen atom attached to R e and R f ), which are each independently selected from the group consisting of N(R d ), NH, O, and S;

-L 1 is a bond or C 1-3 alkylene;

-L 2 is —O—, —N(H)—, —S(O) 0-2 —, or a bond;

R h is selected from the group consisting of:

C 3-8 cycloalkyl or C 3-8 cycloalkenyl, each optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

heterocyclyl or heterocycloalkenyl, wherein the heterocyclyl or heterocycloalkenyl has 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , wherein the heterocyclyl or heterocycloalkenyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 and wherein the heteroaryl ring is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy; and

C 6-10 aryl, which is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

-L 3 is a bond or C 1-3 alkylene;

-L 4 is —O—, —N(H)—, —S(O) 0-2 —, or a bond;

R i is selected from the group consisting of:

C 3-8 cycloalkyl or C 3-8 cycloalkenyl, each optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

heterocyclyl or heterocycloalkenyl, wherein the heterocyclyl or heterocycloalkenyl has 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , wherein the heterocyclyl or heterocycloalkenyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 and wherein the heteroaryl ring is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy; and

C 6-10 aryl, which is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy; and

each occurrence of R′ and R″ is independently selected from the group consisting of: H, —OH, C 1-4 alkyl, C 6-10 aryl optionally substituted with 1-2 substituents selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl, and heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 and wherein the heteroaryl ring is optionally substituted with 1-4 substituents independently selected from the group consisting of halo, —OH, NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , C 1-4 alkyl, and C 1-4 haloalkyl; or R′ and R″ together with the nitrogen atom to which each is attached forms a ring of 3-8 ring atoms, wherein the ring has: (a) 1-7 ring carbon atoms, each of which is substituted with 1-2 substituents independently selected from the group consisting of H and C 1-3 alkyl; and (b) 0-3 ring heteroatoms (in addition to the nitrogen atom attached to R′ and R″), which are each independently selected from the group consisting of N(H), N(C 1-6 alkyl), O, and S;

provided that one or more of a), b), and c) apply:

a) one or more of Z, Y 1 , Y 2 , Y 3 , and Y 4 in the ring below

is an independently selected heteroatom;

b) the ring that includes Z, Y 1 , Y 2 , Y 3 , and Y 4 is partially unsaturated; or

c) Z is a bond; and

further provided that the compound is other than:

2 . The compound of claim 1 , wherein

is aromatic.

3 . The compound of claims 1 or 2 , wherein 1-2 of Y 1 , Y 2 , and Y 3 is independently N or NR 2 , such as N; and each of the remaining of Y, Y 2 , and Y 3 is an independently selected CR 1 , optionally wherein Z is CR 1 , such as:

wherein the

 moiety

 wherein the asterisk denotes point of attachment to Y 4 .

4 . The compound of claims 1 or 2 , wherein Z is N; and optionally each of Y 1 , Y 2 , and Y 3 is an independently selected CR 1 , such as:

wherein the

 moiety is

 such as

 wherein the asterisk denotes point of attachment to Y 4 .

5 . The compound of any one of claims 1 - 4 , wherein X 1 is NR 2 , such as wherein X 1 is NH; and optionally wherein Y 4 is C.

6 . The compound of any one of claims 1 - 5 , wherein X 2 is CR 5 , such as wherein X 2 is CH; and optionally wherein Y 4 is C.

7 . The compound of any one of claims 1 - 6 , wherein 1-2 occurrences of R 1 is other than H, such as:

wherein one occurrence of R 1 is selected from the group consisting of: halo; cyano; C 1-6 alkyl optionally substituted with 1-2 R a ; C 2-6 alkenyl; C 2-6 alkynyl; C 1-4 haloalkyl; C 1-4 alkoxy; C 1-4 haloalkoxy; —S(O) 1-2 (C 1-4 alkyl); —S(O) 1-2 (NR′R″); —NO 2 ; —C(═O)(C 1-4 alkyl); —C(═O)O(C 1-4 alkyl); —C(═O)OH; and —C(═O)N(R′)(R″), such as:

wherein one occurrence of R 1 is halo, such as —F or —Cl.

8 . The compound of any one of claims 1 - 7 , wherein wherein Q-A is defined according to (A), optionally wherein Q is NH.

9 . The compound of any one of claims 1 - 8 , wherein A is —(Y A1 ) n —Y A2 .

10 . The compound of any one of claims 1 - 9 , wherein Y A1 is C 1-6 alkylene, which is optionally substituted with 1-4 R a , such as:

wherein Y A1 is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH(CF 3 )—, —CH 2 CH(OH)—,

 such as:

wherein Y A1 is —CH 2 —.

11 . The compound of any one of claims 1 - 10 , wherein YA 2 is phenyl substituted with 1-3 R c , wherein one R c is at the ring carbon para to the point of attachment to YA 1 ; or

wherein Y A2 is phenyl substituted with 1-3 R c , wherein 1-2 R c is at the ring carbons meta to the point of attachment to Y A1 ; or

wherein Y A2 is phenyl substituted with 1-3 R c , wherein 1-2 R c is at the ring carbons ortho to the point of attachment to Y A1 ; or

wherein Y A2 is C 7-10 bicyclic aryl, which is optionally substituted with 1-3 R c , such as wherein Y A2 is selected from the group consisting of: naphthyl, such as

 indanyl, such as

 and tetrahydronapthyl, each of which is optionally substituted with 1-3 R c );

optionally wherein each occurrence of R c is independently selected from the group consisting of: halo; cyano; C 1-10 alkyl which is optionally substituted with 1-6 independently selected R a ; C 2-6 alkenyl; C 2-6 alkynyl; C 1-4 alkoxy; C 1-4 haloalkoxy; —S(O) 1-2 (C 1-4 alkyl); —NR e R f ; —C 1-4 thioalkoxy; —C(═O)(C 1-10 alkyl); —C(═O)(OH); —C(═O)O(C 1-4 alkyl); and -L 1 -L 2 -R h .

12 . The compound of any one of claims 1 - 10 , wherein Y A2 is heteroaryl of 5-14 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heteroaryl ring is optionally substituted with 1-4 independently selected R c ;

optionally wherein each occurrence of R c is independently selected from the group consisting of: halo; cyano; C 1-10 alkyl which is optionally substituted with 1-6 independently selected R a ; C 2-6 alkenyl; C 2-6 alkynyl; C 1-4 alkoxy; C 1-4 haloalkoxy; —S(O) 1-2 (C 1-4 alkyl); —NR e R f ; —C 1-4 thioalkoxy; —C(═O)(C 1-10 alkyl); —C(═O)(OH); —C(═O)O(C 1-4 alkyl); and -L 1 -L 2 -R h .

13 . The compound of any one of claims 1 - 10 , wherein Y A2 is C 3-6 cycloalkyl or C 3-6 cycloalkenyl, each of which is substituted with 1-4, such as 1-2, R b ; such as: wherein Y A2 is cyclopropyl, cyclopentyl, or cyclohexyl, each of which is optionally substituted with 1-2 R b ; or

wherein Y A2 is bicyclic, tricyclic, or polycyclic C 7-20 , such as C 7-12 , cycloalkyl or C 7-20 , such as C 7-12 , cycloalkenyl, each optionally substituted with 1-2 R b , such as: wherein Y A2 is selected from the group consisting of: spiro[5.5]undecanyl, such as

 bicyclo[2.2.1]hept-2-enyl, such as

 bicyclo[2.2.1]heptanyl, such as

 spiro[2.5]octanyl, such as

 and adamantly, such as

optionally wherein each occurrence of R b is independently selected from the group consisting of: C 1-10 alkyl optionally substituted with 1-6 independently selected R a ; C 1-4 haloalkyl; —F; —Cl; —Br; cyano; C 1-4 alkoxy; C 1-4 haloalkoxy; —C(═O)(C 1-10 alkyl); —C(═O)O(C 1-4 alkyl); —S(O) 1-2 (C 1-4 alkyl); oxo; cyano; and -L 1 -L 2 -R h .

14 . The compound of any one of claims 1 - 7 , wherein Q-A is as defined according to (B); and E a ring of 5-8 ring atoms, wherein aside from the nitrogen atom present, 0-3 additional ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the ring is optionally substituted with 1-4 independently selected R b , such as:

wherein E is piperidinyl which is optionally substituted with 1-2 independently selected R b , such as: wherein E is

 and R b is C 1-6 alkyl.

15 . The compound of claim 1 , wherein the compound is a compound of Formula (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), or (I-8), or a pharmaceutically acceptable salt thereof:

wherein n1 is 0, 1, or 2; each of R cA and R cB is an independently selected R c ; and R 7 is H or C 1-4 alkyl; or

wherein n1 is 0, 1, or 2; each of R cA and R cB is an independently selected R c ; and R 7 is H or C 1-4 alkyl; or

wherein one of Q 1 and Q 2 is N; the other one of Q 1 and Q 2 is CH; n1 is 0, 1, or 2; each of R cA and R cB is an independently selected R c ; and R 7 is H or C 1-4 alkyl; or

wherein one of Q 1 , Q 2 , Q 3 , and Q 4 is N; each of the remaining of Q 1 , Q 2 , Q 3 , Q 4 is CH; n1 is 0, 1, or 2; and each of R cA and R cB is an independently selected R c ; and R 7 is H or C 1-4 alkyl; or

wherein B 1 is selected from the group consisting of:

(a) bicyclic or tricyclic heteroaryl of 7-14 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heteroaryl ring is optionally substituted with 1-4 independently selected R c ; and

(b) C 7-10 bicyclic aryl, which is optionally substituted with 1-3 R c ;

and R 7 is H or C 1-4 alkyl; or

wherein n2 is 0, 1, or 2; each of R bA and R bB is an independently selected R b ; and R 7 is H or C 1-4 alkyl; or

wherein n2 is 0, 1, or 2; each of R bA and R bB is an independently selected R b ; and R 7 is H or C 1-4 alkyl; or

wherein B 2 is: bicyclic, tricyclic, or polycyclic C 7-20 cycloalkyl or C 7-20 cycloalkenyl, each optionally substituted with 1-2 R b ; and

R 7 is H or C 1-4 alkyl;

optionally wherein X 1 is NH, X 2 is CH, and Y 4 is C in Formula (I-1), (I-2), (I-3), (I4), (I-5), (I-6), (I-7), or (I-8);

optionally wherein R 6 is H in Formula (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), or (I-8);

optionally wherein R cA in Formula (I-1), (I-2), (I-3), or (I-4) is selected from the group consisting of: R cA is selected from the group consisting of: halo; cyano; C 1-10 alkyl which is optionally substituted with 1-6 independently selected R a ; C 2-6 alkenyl; C 2-6 alkynyl; C 1-4 alkoxy; C 1-4 haloalkoxy; —S(O) 1-2 (C 1-4 alkyl); —NR e R f ; —C 1-4 thioalkoxy; —C(═O)(C 1-10 alkyl); —C(═O)(OH); —C(═O)O(C 1-4 alkyl); and -L 1 -L 2 -R h ; and

optionally wherein R bA in Formula (I-6) or (I-7) is selected from the group consisting of: C 1-10 alkyl which is optionally substituted with 1-6 independently selected R a ; —F; —Cl; and -L 1 -L 2 -R h .

16 . The compound of claim 1 , wherein the compound is selected from the group consisting of the compounds delineated in Table C1, or a pharmaceutically acceptable salt thereof.

17 . A pharmaceutical composition comprising a compound of claims 1 - 16 and one or more pharmaceutically acceptable excipients.

18 . A method for inhibiting STING activity, the method comprising contacting STING with a compound as claimed in any one of claims 1 - 16 , or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition as claimed in claim 17 .

19 . A method of inducing an immune response in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound as claimed in any one of claims 1 - 16 , or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition as claimed in claim 17 .

20 . A method of treatment of disease, disorder, or condition associated with STING, such as a disease, disorder, or condition, in which increased STING signaling, such as excessive STING signaling, contributes to the pathology and/or symptoms and/or progression of the disease, such as cancer, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1 - 16 , or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 17 .